https://www.selleckchem.com/pr....oducts/Fasudil-HCl(H
which tended to improve by 8.6 (9.7) and 13.9 (15., respectively, at 12-months. MOS-Sleep and EQ-5D remained steady during the study, except pain/discomfort and anxiety/depression which went from 58.7% and 49.6% to 29.6% and 26.9%, respectively. At baseline, HADS showed a mean (SD) anxiety of 8.7 (4.5) and depression 5.1 (4.4), decreasing to 7.0 (4.3) and 4.7 (4.3), respectively, at 12-months. Although most CU patients are treated with NS-H1AH, disease activity is still important, negatively affecting patients' QoL, wo
Like
Comment
Share
